Gabapentin Use in Benzodiazepine Dependence and Detoxification

Dear Edi tor:
Once pa tients be come de pend ent on ben zo di azepines, dis con tinu ing them of ten proves vex ing. De toxi fi ca tion ends up be ing pro longed or un suc cess ful due to with drawal or re-emergent anxiety (1) , as well as to the need for an ex ternal source of con trol (2) . Ga bap en tin is a novel an ti con vul sant, struc tur ally analogous to gamma-aminobutyric acid (GABA), that pro motes GABA re lease via un known mecha nisms (3) . It has been re ported help ful in the man agement of pain syn dromes (4), anxi ety (5) (6) (7) , and al co hol with drawal (8) . We pres ent a case wherein de toxi fi ca tion from ben zo di azepines was aided by the use of ga bap en tin; there have been no pre vi ous simi lar re ports.
Mrs A was a 49-year-old woman with a 7-year his tory of con tinu ous de pendence on 12 to15 mg of al pra zo lam daily. Tol er ance, with drawal, and loss of control char ac ter ized her use, with marked in ter fer ence in her work and home life. Her ben zo di azepine de pend ence was com pli cated by Fiorinal-C½ and diphen hy dramine abuse. Com pound ing mat ters was a his tory of re cur rent panic and gen er al ized anxi ety, fre quent depres sive epi sodes with sui ci dal ity, and so ma ti za tion. She en tered hos pi tal af ter a sui cide at tempt in which she took 60 to 75 mg of al pra zo lam. De spite mul ti ple so matic com plaints, her physi cal status was un re mark able, with nor mal re nal func tion.
She was con tin ued on her pre vi ous paroxet ine at 20 mg daily. Al pra zo lam, barbi tu rates, opi ates, and an ti his ta mines were stopped. A clo naze pam ta per was started at 2 mg twice daily, with dose as needed for break through with drawal or marked anxi ety. On 1 mg of clo naze pam daily her ta per stalled; over whelm ing anxi ety, tremor, and af fec tive in sta bil ity pre vented fur ther dose re duc tion. Due to her in sta bil ity and con tin ued ben zo diazepine use, she was de clined en try into resi den tial ad dic tion treat ment. She refused car be mazepine be cause of po tential side ef fects. She in stead started on 200 mg of ga bap en tin 3 times daily. Initially as her symp toms of anxi ety, tremor, and af fec tive la bil ity rap idly decreased, she de scribed ga bap en tin as "feel ing like al pra zo lam." Clo naze pam was then ta pered off. Within 3 weeks of ad mis sion, she was benzodiazepinefree. The sub jec tive, alprazolam-like effect faded, but anx ious symp toms remained con trolled, with lit tle crav ing for ben zo di azepines or other sub stances, includ ing ciga rettes. She de nied any adverse ef fects from the medi ca tion, ex cept for short-term se da tion. The to tal daily dose of ga bap en tin re mained low (600 mg daily). Off ben zo di azepines, her men tal state im proved, al low ing discharge from hos pi tal and com mencement of out pa tient ad dic tion treat ment. Two months later, she re mained ab sti nent.
Car be mazepine has been used in ben zodi azepine de toxi fi ca tion (1), but its poten tial for ad verse ef fects ne ces si tates close moni tor ing and labo ra tory test ing. These con cerns pre cluded its use in this case. Al ter na tively, pro longed ben zo diazepine ta pers of ten fail (1, 9) or can obstruct en try into ad dic tion treat ment. In this case, the ad di tion of ga bap en tin appeared to ease the ben zo di azepine detoxi fi ca tion pro cess ap pre cia bly, short en ing over all with drawal time while side step ping com monly en countered prob lems. Ga bap en tin has a relatively be nign side-effect pro file with few known drug in ter ac tions, a wide thera peu tic win dow, does not re quire blood moni tor ing, and is not me tabolized by the liver (3, 4) . Its use may thus of fer a rea son able al ter na tive, be yond the cur rently avail able op tions, for withdraw ing benzodiazepine-dependent pa tients.
